Intercept failed NASH candidate precipitated Alfasigma acquisition Markets September 30, 2023 Mohammed Haneefa Nizamudeen After the failure of Intercept Prescribed drugs’ (ICPT) Ocaliva (obeticolic acid) for nonalcoholic steatohepatitis (NASH) in June,…
Canaccord cuts Intercept to hold, calls Alfasigma deal “best possible outcome” (ICPT) Markets September 27, 2023 Maksim Labkouski Intercept Prescribed drugs (NASDAQ:ICPT) has been downgraded to carry by Canaccord Genuity within the wake of stories that…
